Beaver Stephen J sold $1.7M of BHE

Beaver Stephen J (SVP, General Counsel and CLO) sold 20,000 shares of BENCHMARK ELECTRONICS INC (BHE) at $86.25 ($1.72M total) on 2026-06-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Beaver Stephen J
Published Jun 11, 2026, 9:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 11, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BHE
Neutral
high confidence
Mentioned
$BHE
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BHENeutralLow
01

Why it matters

The only new information is the size, price, and timing of the officer’s scheduled open-market sale; it does not include any new corporate event.

02

Market read

Useful for monitoring insider activity, but unlikely to materially change valuation expectations absent additional company catalysts.

03

What to watch

The filing does not state intent beyond the plan; traders should avoid extrapolating fundamentals from a single scheduled sale without corroborating news (earnings, guidance, contracts, or investigations).

Relevance 5/10Novelty 5/10Timing: filed 2026-06-11 (transaction dated 2026-06-11)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Benchmark Electronics.

Company-level read

Ticker impact

$BHENeutralHigh confidence
Context

Benchmark Electronics disclosed an SVP/General Counsel/CLO open-market sale of 20,000 shares at $86.25 on 2026-06-11 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a standard insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, with no accompanying company-specific operational or guidance change disclosed.

Market effects

No sector read-across; this is company-specific insider liquidity/positioning rather than a sector catalyst.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification/tax planning and may not reflect bearish views, especially when executed under a 10b5-1 plan.

Key entities

  • BENCHMARK ELECTRONICS INC

    Company whose insider transaction was reported on SEC Form 4.

  • Beaver Stephen J

    SVP, General Counsel and CLO who sold 20,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$BHEHighAI 8/10

What Benchmark Electronics (BHE) Said on Its Q3 Earnings Call

Benchmark Electronics (BHE) reported Q3 growth in four of five end markets, with Semi-Cap revenue up 30% YoY. The company expects continued growth in 2027. It raised its Q4 and full-year outlook, forecasting 19% YoY revenue growth at the midpoint. BHE is investing in capacity and managing supply-chain constraints.

$BHEHighAI 8/10

Benchmark Electronics (BHE) Q3 2026 Earnings Call Transcript

Benchmark Electronics (BHE) reported Q3 2026 revenue of $811M, up 19% YoY, with non-GAAP EPS of $0.84, up 35% YoY. The company raised its full-year revenue outlook to over $3B. Semi-Cap and AC&C sectors drove growth, while Medical and Industrial also showed improvement. BHE expects Q4 revenue between $815M and $855M, with non-GAAP EPS between $0.85 and $0.91.

$BHEMedAI 8/10

Benchmark Electronics Inc (BHE) (Q3 2026) Earnings Call Highlights: Record Revenue

Benchmark Electronics (BHE) reported Q3 2026 earnings with record revenue and raised guidance. Aerospace & Defense revenue declined 1% YoY, and supply chain challenges persist. Inventory rose 16% sequentially. CEO David Moezidis cited customer forecasts and program ramps for growth confidence. The company expects capacity to support growth through 2027 and targets earnings growth at 1.5-2x revenue growth. Medical sector remains strong, with growth extending into 2028.